[{"address1": "Cedar Brook Corporate Center", "address2": "4-B Cedar Brook Drive", "city": "Cranbury", "state": "NJ", "zip": "08512", "country": "United States", "phone": "609 495 2200", "fax": "609 495 2202", "website": "https://palatin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl  Spana Ph.D.", "age": 61, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 979000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Wills CPA, MST", "age": 66, "title": "CFO, COO, Executive VP, Treasurer & Secretary", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 910550, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Burns  McClellan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen A. Slusher Esq.", "title": "Chief Legal Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Raizman M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James E. Hattersley", "age": 63, "title": "Senior Vice President of Business Development", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Dodd Ph.D.", "title": "Senior Vice President of Preclinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Jordan", "title": "Senior Vice President of Program Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.45, "open": 3.37, "dayLow": 2.56, "dayHigh": 3.44, "regularMarketPreviousClose": 3.45, "regularMarketOpen": 3.37, "regularMarketDayLow": 2.56, "regularMarketDayHigh": 3.44, "payoutRatio": 0.0, "beta": 1.082, "forwardPE": -3.9696965, "volume": 670029, "regularMarketVolume": 670029, "averageVolume": 216983, "averageVolume10days": 590770, "averageDailyVolume10Day": 590770, "bid": 0.0, "ask": 0.0, "bidSize": 1000, "askSize": 1100, "marketCap": 47393176, "fiftyTwoWeekLow": 1.43, "fiftyTwoWeekHigh": 5.0, "priceToSalesTrailing12Months": 7.7821293, "fiftyDayAverage": 2.4024, "twoHundredDayAverage": 2.2763, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 31400690, "profitMargins": 0.0, "floatShares": 13167595, "sharesOutstanding": 13737100, "sharesShort": 552543, "sharesShortPriorMonth": 667675, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.0402, "heldPercentInsiders": 0.03975, "heldPercentInstitutions": 0.0575, "shortRatio": 4.56, "shortPercentOfFloat": 0.041100003, "impliedSharesOutstanding": 18089000, "bookValue": -0.409, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -25174878, "trailingEps": -1.63, "forwardEps": -0.66, "lastSplitFactor": "1:25", "lastSplitDate": 1661904000, "enterpriseToRevenue": 5.156, "enterpriseToEbitda": -1.029, "52WeekChange": -0.2084592, "SandP52WeekChange": 0.20374417, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PTN", "underlyingSymbol": "PTN", "shortName": "Palatin Technologies, Inc.", "longName": "Palatin Technologies, Inc.", "firstTradeDateEpochUtc": 876922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef61cf2b-791e-37b7-b04c-9ccb76a1630d", "messageBoardId": "finmb_32651", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.62, "targetHighPrice": 70.0, "targetLowPrice": 6.0, "targetMeanPrice": 42.0, "targetMedianPrice": 50.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 5524973, "totalCashPerShare": 0.402, "ebitda": -30526368, "totalDebt": 934325, "quickRatio": 0.505, "currentRatio": 0.72, "totalRevenue": 6090001, "revenuePerShare": 0.528, "returnOnAssets": -0.99135, "returnOnEquity": -14.141911, "grossProfits": -18195369, "freeCashflow": -19437220, "operatingCashflow": -25744074, "revenueGrowth": 1.422, "grossMargins": -2.6042898, "ebitdaMargins": 0.0, "operatingMargins": -2.9007401, "financialCurrency": "USD", "trailingPegRatio": null}]